E815
TEAS SECTION 8 & 15 RECEIVED
06/04/2026
Back to search
Official data from USPTO
AZURITY PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
06/05/2026
Trademark type
Combined
Nice classes
5
Filing date
05/30/2019
Registration date
11/24/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/24/2020
Last transaction
06/05/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
08/31/2020
First use in commerce
08/31/2020
Drawing code
3
Owner type
03
Owner location
WOBURN, MA, US
Examiner
DIBLE, JONATHON I
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a series of generally hexagonal shaded polygons forming a swirl with a shaded circle at the top of the swirl, with the shapes being colored dark orange, orange, yellow, green, turquoise, dark turquoise, light blue, blue, navy, and purple, all to the left of the purple stylized wording "AZURITY" above the turquoise stylized wording "PHARMACEUTICALS".
Holders and representatives
Holders
AZURITY PHARMACEUTICALS, INC.
CutisPharma, Inc.
Representatives
Douglas R. Wolf WOLF, GREENFIELD & SACKS, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicinestopical anti-inflammatory and ultrasound gelspain and gastrointestinal disorders treatment medicinesanti-inflammatoryantimicrobialantifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorderscolitismuscle spasminfectious diseasesacid-reflux diseaseulcer diseaseurological disorders; antibiotics; pharmaceutical products for the treatment of painthyroid disordersgastrointestinal disordersgastroesophageal disordersinflammationinfectionsfungal diseases and disorderscardiovascular diseases and disorderscolitismuscle spasmattention deficit hyperactivity disordersinfectious diseasesacid-reflux diseaseulcer diseaseurological disorders having vancomycinenalaprillisinoprilmethotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of painthyroid disordersgastrointestinal disordersgastroesophageal disordersinflammationinfectionsfungal diseases and disorderscardiovascular diseases and disorderscolitismuscle spasmattention deficit hyperactivity disordersinfectious diseasesacid-reflux diseaseulcer diseaseurological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disordersfor the treatment and prevention of renaloncologicalinflammatorygastrointestinalgastroesophagealcardio-vascular diseases and disorders
Publications
History of USPTO decisions and trademark events.
26 publications found
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/24/2025
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
03/19/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
11/24/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/22/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/21/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/21/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/20/2020
IUAF
USE AMENDMENT FILED
10/06/2020
EISU
TEAS STATEMENT OF USE RECEIVED
10/06/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/29/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/28/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/03/2020
PUBO
PUBLISHED FOR OPPOSITION
03/03/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/12/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/30/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/29/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/29/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/29/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/09/2019
GNRT
NON-FINAL ACTION E-MAILED
08/09/2019
CNRT
NON-FINAL ACTION WRITTEN
08/09/2019
DOCK
ASSIGNED TO EXAMINER
08/08/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/15/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/14/2019
NWAP
NEW APPLICATION ENTERED
06/03/2019
Continuous trademark protection
Get notified about every new filing that threatens AZURITY PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.